Reference health
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
32/32 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 32 checked references that resolve
resolves10.1016/j.neuron.2006.09.011
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
resolves10.1093/brain/112.1.133
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY
resolves10.1002/ana.410390304
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
resolves10.1212/WNL.45.7.1268
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
resolves10.1002/ana.21079
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial
resolves10.1056/NEJMoa044397
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
resolves10.1016/j.jneuroim.2006.07.006
Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness
resolves10.1007/BF00313168
Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS
resolves10.1038/5532
Identification of autoantibodies associated with myelin damage in multiple sclerosis
resolves10.4049/jimmunol.175.3.1974
Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein
resolves10.1016/S0165-5728(03)00002-X
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions
resolves10.1093/brain/awm038
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
resolves10.4049/jimmunol.163.9.5133
B Cell Repertoire Diversity and Clonal Expansion in Multiple Sclerosis Brain Lesions
resolves10.4049/jimmunol.164.5.2782
Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients
resolves10.1073/pnas.0402455101
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis
resolves10.1002/ana.410430214
Restricted use of V<sub>H</sub>4 Germline segments in an acute multiple sclerosis brain
resolves10.1016/j.jneuroim.2005.05.006
Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions
resolves10.1212/WNL.54.6.1227
Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response
resolves10.4049/jimmunol.178.10.6092
Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis
resolves10.1182/blood.V83.2.435.435
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
resolves10.1042/bst0250705
Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
resolves10.1002/ana.1032
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
resolves10.1002/ana.20890
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation
resolves10.1177/0091270007305297
Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response
resolves10.1182/blood.V94.7.2217.419k02_2217_2224
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
resolves10.1002/art.22025
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
The 1 reference without a DOI — listed, not checked
no DOI — not checkedr027
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1056/nejmoa0706383"><img src="https://citestamp.com/citestamped/10.1056/nejmoa0706383/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1056/nejmoa0706383)